



## Press Release

### **Ermium Therapeutics to present promising preclinical data highlighting the therapeutic potential of Ermium immunomodulators for the treatment of systemic lupus erythematosus at the annual ACR Convergence 2022 conference**

---

**Paris, France, November 10<sup>th</sup>, 2022** – Ermium Therapeutics SAS, a discovery-stage biotechnology company developing innovative therapies for auto-immune diseases, is announcing today that Dr Annegret Van der Aa, CSO/CDO will be presenting promising preclinical data on Ermium immunomodulators for the treatment of systemic lupus erythematosus (SLE) and other type I interferon-driven diseases at the ACR Convergence 2022 conference to be held between November 10<sup>th</sup> – 14<sup>th</sup> in Philadelphia, US, and virtually.

**Poster title:** CXCR4-targeted Functionally Selective Immunomodulator Shows Robust Efficacy in Pristane-induced Murine Lupus Model (poster 1723)

**Authors:** Annegret Van der Aa, Simon Tessier, Jean-Philippe Herbeuval, and Joël Crouzet.

**Session Title:** SLE – Animal Models

**Session Date and time:** November 14<sup>th</sup> at 1:00 – 3:00 PM ET on the conference digital poster platform (poster available on conference website since 31 October 2022)

#### **About Ermium Therapeutics**

Ermium Therapeutics, a discovery-stage company dedicated to R&D in the auto-immune disease space, was founded in June 2019. Ermium immunomodulators are orally available compounds aimed to be developed for auto-immune disease indications, particularly interferonopathies, including systemic lupus erythematosus. Such immunomodulators exhibit potent immunomodulating properties by efficiently downmodulating the release of type I interferons, and also other key proinflammatory cytokines. The company has obtained in vivo POC in different auto-immune / inflammatory murine disease models. Ermium Therapeutics is based at the Paris Biotech Santé Incubator – Accelerator located at the Cochin Hospital in Paris. The company has raised €12.3 M from Kurma Partners, Fountain Healthcare Partners, Domain Therapeutics, Eurazeo, and Erganeo, while receiving grants and soft loans from Bpifrance, the French agency for innovation. Ermium Therapeutics has signed a worldwide exclusive license agreement on intellectual property from the CNRS and the Université Paris Cité through an agreement with Erganeo. [www.ermium.com](http://www.ermium.com)

#### **For more information please contact:**

Ermium Therapeutics  
Dr Joël Crouzet  
Chief Executive Officer  
[contact@ermium.com](mailto:contact@ermium.com)